Avapritinib versus Placebo in Indolent Systemic MastocytosisJason Gotlib, Robyn M. Scherber, Hanneke Oude Elberink et al.|NEJM Evidence|2023Cited by 74
Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasm‐associated venous thromboembolism in a large tertiary centre in the UKNatalia Curto‐García, Claire Harrison, Andrew J. Doyle et al.|British Journal of Haematology|2020Cited by 31
Proposed European Competence Network on Mastocytosis—American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic MastocytosisJason Gotlib, Andreas Reiter, Juliana Schwaab et al.|The Journal of Allergy and Clinical Immunology In Practice|2022Cited by 20
Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (<i>JAK2</i>) V617F and KIT proto‐oncogene, receptor tyrosine kinase (<i>KIT</i>) D816V mutationsNicole Naumann, Juliana Schwaab, Johannes Lübke et al.|British Journal of Haematology|2021Cited by 17